Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report

BACKGROUND: NRG1 fusions are rare oncogenic drivers in solid tumors, and the incidence of NRG1 fusions in non-small cell lung cancer (NSCLC) was 0.26%. It is essential to explore potential therapeutic strategies and efficacy predictors for NRG1 fusion-positive cancers. CASE PRESENTATION: We report a...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Xin, Zhang, Ping, Bie, Zhixin, Song, Chenhui, Zhang, Min, Ma, Di, Cui, Di, Cheng, Gang, Li, Hui, Lei, Yan, Su, Xiaoxing, Wu, Wendy, Li, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428614/
https://www.ncbi.nlm.nih.gov/pubmed/37587479
http://dx.doi.org/10.1186/s12957-023-03129-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428614/
https://www.ncbi.nlm.nih.gov/pubmed/37587479
http://dx.doi.org/10.1186/s12957-023-03129-z

Ejemplares similares